Maravai LifeSciences Reports $50M Annualized Cost Reduction Plan, Targets Positive EBITDA by 2026

Maravai LifeSciences Holdings plans to reduce its annualized costs by $50M as part of a new strategy to achieve positive EBITDA by 2026. CEO Bernd Brust highlighted the need for change to realize the company's full potential, noting that the $50M cost reduction plan is a first step towards this goal. The company aims to reach positive EBITDA by 2026, a significant shift from its previous expectations.

Title: Maravai LifeSciences Announces $50 Million Annual Cost Reduction Plan

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has announced a significant organizational restructuring and cost reduction initiative aimed at achieving more than $50 million in annualized cost savings. The company aims to reach positive Adjusted EBITDA by the second half of 2026, a significant milestone for the global life science reagents and services provider.

The announcement was made on August 11, 2025, with the appointment of Bernd Brust as the new Chief Executive Officer (CEO) and Raj Asarpota as the Chief Financial Officer (CFO). Brust emphasized the need for cost reduction to align the company's operational needs with its current size and to realize its full potential. The restructuring and cost reduction initiatives are expected to impact various aspects of the business, including labor, facilities, capital expenditures, and productivity.

The company reported a 31.7% decrease in quarterly revenue for the second quarter of 2025, driven primarily by a lack of high-volume CleanCap orders for commercial phase vaccine programs. Despite this, the company's base business revenue, excluding revenue from CleanCap, grew by 5% year-over-year, led by strong demand for its Cygnus products and services.

Maravai LifeSciences also expects to incur restructuring charges of approximately $8.0 million to $9.0 million in the second half of 2025, primarily consisting of employee severance, benefits, and related costs. These charges are subject to various assumptions, and actual expenses may differ materially from the estimates.

The new leadership team is in the process of a comprehensive business review and forecasting process, and revenue guidance for 2025 has been withdrawn and suspended. The company will reinstate guidance once this process is complete.

Maravai LifeSciences is also expanding its CDMO enablement strategy with a new license and supply agreement for CleanCap with Thermo Fisher Scientific. Additionally, the company has launched an mRNA synthesis kit leveraging several high-performing products from TriLink BioTechnologies, simplifying the in vitro transcription (IVT) workflow for researchers worldwide.

The company's financial results for the second quarter of 2025 include a net loss of $(69.8) million and Adjusted EBITDA of $(10.4) million. The six-month results show a net loss of $(122.7) million and Adjusted EBITDA of $(21.0) million, compared to the same period in the prior year.

Maravai LifeSciences is scheduled to host a conference call today at 2:00 p.m. PT/5:00 p.m. ET to discuss its financial results for the second quarter of 2025 and other business updates. The call will be available via telephone and webcast on the company's investor relations website.

References:
[1] https://www.quiverquant.com/news/Maravai+LifeSciences+Announces+Organizational+Restructuring+and+Cost+Reduction+Initiatives+Aiming+for+%2450+Million+in+Annual+Savings